Safety, tolerability and efficacy of indacaterol, a novel once-daily β2-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial
J Beier, P Chanez, JB Martinot, AJM Schreurs… - Pulmonary …, 2007 - Elsevier
In patients with chronic obstructive pulmonary disease (COPD) classified as moderate
onwards, Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines
recommend regular treatment with one or more long-acting bronchodilators, such as β2-
agonists or anticholinergics. In contrast to currently available long-acting β2-agonists, which
have a duration of action of 12h, indacaterol has demonstrated effective 24-h
bronchodilation on once-daily dosing. A double-blind, randomised, placebo-controlled study …
onwards, Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines
recommend regular treatment with one or more long-acting bronchodilators, such as β2-
agonists or anticholinergics. In contrast to currently available long-acting β2-agonists, which
have a duration of action of 12h, indacaterol has demonstrated effective 24-h
bronchodilation on once-daily dosing. A double-blind, randomised, placebo-controlled study …
以上显示的是最相近的搜索结果。 查看全部搜索结果